白雲山(600332.SH):新增南沙科創母基金成為沃博聯廣藥基金的有限合夥人
格隆匯6月26日丨白雲山(600332.SH)公佈,2024年6月26日,公司召開第九屆董事會第十一次會議,審議通過了《關於參與投資的沃博聯廣藥(廣州)股權投資合夥企業(有限合夥)新增有限合夥人暨關聯交易的議案》,同意新增南沙科創母基金成為沃博聯廣藥基金的有限合夥人,基金規模由90,000.00萬元增至100,000.00萬元,廣藥基金對基金的實際出資未發生變化。合夥人一致同意修訂投資方式、南沙科創母基金返投要求等合夥協議條款並重新簽署《合夥協議》。本次後續募集完成後,沃博聯廣藥基金後續募集將全部完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.